Alkermes Plc (NASDAQ:ALKS) Director Richard F. Pops sold 20,000 shares of Alkermes stock in a transaction that occurred on Tuesday, May 22nd. The shares were sold at an average price of $45.46, for a total transaction of $909,200.00. Following the completion of the transaction, the director now owns 686,352 shares of the company’s stock, valued at approximately $31,201,561.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Alkermes stock opened at $45.77 on Friday. Alkermes Plc has a 52-week low of $41.15 and a 52-week high of $71.22. The company has a quick ratio of 2.52, a current ratio of 2.83 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $7.04 billion, a P/E ratio of -123.70 and a beta of 1.81.
Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Thursday, April 26th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Alkermes had a negative return on equity of 3.13% and a negative net margin of 16.18%. The firm had revenue of $225.20 million during the quarter, compared to analysts’ expectations of $219.51 million. During the same quarter in the prior year, the firm earned ($0.18) EPS. The firm’s revenue was up 17.4% compared to the same quarter last year. equities research analysts anticipate that Alkermes Plc will post -0.66 EPS for the current fiscal year.
A number of brokerages recently weighed in on ALKS. ValuEngine cut shares of Alkermes from a “sell” rating to a “strong sell” rating in a report on Tuesday. Citigroup upgraded shares of Alkermes from a “neutral” rating to a “buy” rating and set a $62.00 price objective for the company in a report on Wednesday, May 16th. BidaskClub upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a report on Wednesday, May 16th. Bank of America began coverage on shares of Alkermes in a report on Friday, May 11th. They issued a “buy” rating and a $56.00 price objective for the company. Finally, TheStreet cut shares of Alkermes from a “c-” rating to a “d+” rating in a report on Friday, April 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $59.15.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.